Mongolian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
primary immunodeficiency diseases/protease
Холбоосыг санах ойд хадгалдаг
Хуудас 1 -аас 71 үр дүн
Methods for determining human immunodeficiency virus type 2 (HIV-2) protease sensitivity or resistance to antivirals utilizing an inducible yeast expression system
Зөвхөн бүртгэлтэй хэрэглэгчид л нийтлэл орчуулах боломжтой
Нэвтрэх / Бүртгүүлэх
RELATED APPLICATION
This is a .sctn.371 of International Application No. PCT/FR2005/001356, with an international filing date of Jun. 2, 2005 (WO 2006/000693 A1, published Jan. 5, 2006), which is based on French Patent Application No. 04/05945, filed Jun. 2, 2004.
TECHNICAL FIELD
This disclosure
Method of treating human immunodeficiency virus infection using a cyclic protease inhibitor in combination with a reverse transcriptase inhibitor
Зөвхөн бүртгэлтэй хэрэглэгчид л нийтлэл орчуулах боломжтой
Нэвтрэх / Бүртгүүлэх
FIELD OF THE INVENTION
This invention relates to a method of treating human immunodeficiency virus (HIV) infection in a mammal comprising administering to the mammal a therapeutically effective amount of a combination of: (i) at least one cyclic HIV protease inhibitor and (ii) at least one HIV
Human immunodeficiency virus protease inhibitors
Зөвхөн бүртгэлтэй хэрэглэгчид л нийтлэл орчуулах боломжтой
Нэвтрэх / Бүртгүүлэх
FIELD OF INVENTION
The described invention relates to novel human immunodeficiency virus protease inhibitors, pharmaceutical compositions containing at least one such inhibitor, methods of preparing such inhibitors, and methods of utilizing such inhibitors to treat HIV and HIV-related
Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
Зөвхөн бүртгэлтэй хэрэглэгчид л нийтлэл орчуулах боломжтой
Нэвтрэх / Бүртгүүлэх
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to formulations of nanoparticulate human immunodeficiency virus (HIV) protease inhibitor drug substances comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of
Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors
Зөвхөн бүртгэлтэй хэрэглэгчид л нийтлэл орчуулах боломжтой
Нэвтрэх / Бүртгүүлэх
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to formulations of nanoparticulate human immunodeficiency virus (HIV) protease inhibitor drug substances comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of
Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
Зөвхөн бүртгэлтэй хэрэглэгчид л нийтлэл орчуулах боломжтой
Нэвтрэх / Бүртгүүлэх
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to formulations of nanoparticulate human immunodeficiency virus (HIV) protease inhibitor drug substances comprising a cellulosic surface stabilizer. The nanoparticulate formulations have an increased rate of
Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor
Зөвхөн бүртгэлтэй хэрэглэгчид л нийтлэл орчуулах боломжтой
Нэвтрэх / Бүртгүүлэх
FIELD OF THE INVENTION
The present invention relates generally to the field of treatment human beings with Human Immunodeficiency Virus (HIV) infections. The inventors have found that the combination of hydroxyurea (HU), a nucleoside analog, and a protease inhibitor is capable of reducing the
Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor
Зөвхөн бүртгэлтэй хэрэглэгчид л нийтлэл орчуулах боломжтой
Нэвтрэх / Бүртгүүлэх
FIELD OF THE INVENTION
The present invention relates generally to the field of treatment of human beings with Human Immunodeficiency Virus (HIV) infections. The inventors have found that the combination of hydroxyurea (HU), a nucleoside analog, and a protease inhibitor is capable of reducing the
Schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (HIV)
Зөвхөн бүртгэлтэй хэрэглэгчид л нийтлэл орчуулах боломжтой
Нэвтрэх / Бүртгүүлэх
CROSS REFERENCE TO RELATED APPLICATION
This is a National Stage of International Application No. PCT/EP2010/067851, filed 19 Nov. 2010, which claims the benefit of application Ser. No. 09/176,666.7, filed in Europe on 20 Nov. 2009, the disclosures of which Applications are incorporated by reference
Schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (HIV)
Зөвхөн бүртгэлтэй хэрэглэгчид л нийтлэл орчуулах боломжтой
Нэвтрэх / Бүртгүүлэх
FIELD OF INVENTION
The present invention relates to novel schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (HIV), which is responsible for the acquired immune deficiency syndrome (AIDS).
BACKGROUND
The human
Use of HIV protease inhibiting compounds
Зөвхөн бүртгэлтэй хэрэглэгчид л нийтлэл орчуулах боломжтой
Нэвтрэх / Бүртгүүлэх
FIELD OF THE INVENTION
The subject of the present invention is the therapeutic use of a human immunodeficiency virus (HIV) protease inhibiting compound as proteasome modulator.
DESCRIPTION OF RELATED ART
Proteasome, a central enzymatic system in protein degradation both in the cytosol and in the
Process for preparing protease inhibitor intermediates
Зөвхөн бүртгэлтэй хэрэглэгчид л нийтлэл орчуулах боломжтой
Нэвтрэх / Бүртгүүлэх
FIELD OF THE INVENTION
The present invention generally concerns the preparation of cyclic alcohol intermediates useful in the preparation of inhibitors of HIV aspartyl protease. More specifically, the present invention includes a method for the preparation of
Aspartyl protease inhibitors
Зөвхөн бүртгэлтэй хэрэглэгчид л нийтлэл орчуулах боломжтой
Нэвтрэх / Бүртгүүлэх
FIELD OF THE INVENTION
This invention relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus,
Use of amphotericin B derivatives as protease inhibitors
Зөвхөн бүртгэлтэй хэрэглэгчид л нийтлэл орчуулах боломжтой
Нэвтрэх / Бүртгүүлэх
The present invention relates to the use of derivatives of polyene macrolides, in particular amphotericin B, as protease inhibitors, and to the applications of said inhibitors for the production of medicinal products intended in particular for the treatment of infection by the human immunodeficiency
Heterocyclic aspartyl protease inhibitors
Зөвхөн бүртгэлтэй хэрэглэгчид л нийтлэл орчуулах боломжтой
Нэвтрэх / Бүртгүүлэх
FIELD OF THE INVENTION
This invention relates to heterocyclic aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human
Шинжлэх ухаанаар баталгаажсан эмийн өвс ургамлын бүрэн мэдээллийн сан
- 55 хэл дээр ажилладаг
- Шинжлэх ухааны үндэслэсэн ургамлын гаралтай эдгэрэлт
- Ургамлыг дүрсээр таних
- Интерактив GPS газрын зураг - эмийн ургамлыг байршлаар нь тэмдэглэнэ (удахгүй)
- Хайлттай холбоотой шинжлэх ухааны нийтлэлүүдийг уншина уу
- Эмийн өвсийг үр нөлөөгөөр нь хайж олох
- Мэдээллийн судалгаа, клиник туршилт, патентыг цаг тухайд нь сонирхож, зохион байгуул
Шинж тэмдэг эсвэл өвчний талаар бичиж, тус болох ургамлын талаар уншиж, өвслөг ургамлыг бичиж, өвчний эсрэг шинж тэмдгийг үзээрэй.
* Бүх мэдээлэл нь хэвлэгдсэн эрдэм шинжилгээний судалгаанд үндэслэсэн болно
